Recombinant Human CD34 His Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-22751
Key Product Details
Source
E. coli
Tag
His
Conjugate
Unconjugated
Applications
SDS-PAGE
Product Specifications
Description
A recombinant protein with a N-Terminal His-tag and corresponding to the amino acids 32-290 of Human CD34
Source: E.coli
Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MSLDNNGTAT PELPTQGTFS NVSTNVSYQE TTTPSTLGST SLHPVSQHGN EATTNITETT VKFTSTSVIT SVYGNTNSSV QSQTSVISTV FTTPANVSTP ETTLKPSLSP GNVSDLSTTS TSLATSPTKP YTSSSPILSD IKAEIKCSGI REVKLTQGIC LEQNKTSSCA EFKKDRGEGL ARVLCGEEQA DADAGAQVCS LLLAQSEVRP QCLLLVLANR TEISSKLQLM KKHQSDLKKL GILDFTEQDV ASHQSYSQKT
Purity
>90%, by SDS-PAGE
Predicted Molecular Mass
29.7 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Protein / Peptide Type
Recombinant Protein
Scientific Data Images for Recombinant Human CD34 His Protein
![SDS-PAGE: Recombinant Human CD34 His Protein [NBP2-22751]](https://resources.bio-techne.com/images/products/CD34-Protein-SDS-Page-NBP2-22751-img0001.jpg "SDS-PAGE: Recombinant Human CD34 His Protein [NBP2-22751]")
SDS-PAGE: Recombinant Human CD34 His Protein [NBP2-22751]
SDS-Page: CD34 Protein [NBP2-22751]Formulation, Preparation and Storage
NBP2-22751
| Formulation | 20 mM Tris-HCl buffer (pH 8.0), 0.1 M NaCl, 20% glycerol, 1 mM DTT |
| Preservative | No Preservative |
| Concentration | 0.25 mg/ml |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
Background: CD34
CD34 has commonly been used as a marker for the diagnosis and classification of various diseases and pathologies including leukemia and solitary fibrous tumor (SFT) (2,5). In terms of immunohistochemistry and histopathology, CD34 has been the most common marker for SFT and is expressed in ~79% of cases (5). In addition to its use as a cell marker, CD34-postive (CD34+) hematopoietic stem cells have been used therapeutically in patients following radiation or chemotherapy due to their regenerative potential (6). There are several clinical trials showing promising results for CD34+ cell therapy for cardiovascular diseases including heart failure, ischemia, dilated cardiomyopathy, acute myocardial infarction, and angina (6). Besides hematopoietic lineages, CD34 is also expressed in non-hematopoietic cells including mesenchymal stem cells, endothelial cells and progenitors, fibrocytes, muscle satellite cells, and some cancer stem cells (1,3). While the clinical and cell therapy applications of CD34 as a cell marker is well documented, the function of CD34 is less understood but has been implicated in many cellular processes such as adhesion, proliferation, signal transduction, differentiation, and progenitor phenotype maintenance (1,3).
References
1. Sidney, L. E., Branch, M. J., Dunphy, S. E., Dua, H. S., & Hopkinson, A. (2014). Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem cells (Dayton, Ohio), 32(6), 1380-1389. https://doi.org/10.1002/stem.1661
2. Krause, D. S., Fackler, M. J., Civin, C. I., & May, W. S. (1996). CD34: structure, biology, and clinical utility. Blood, 87(1), 1-13
3. Kapoor, S., Shenoy, S. P., & Bose, B. (2020). CD34 cells in somatic, regenerative and cancer stem cells: Developmental biology, cell therapy, and omics big data perspective. Journal of cellular biochemistry, 121(5-6), 3058-3069. https://doi.org/10.1002/jcb.29571
4. Uniprot (P28906)
5. Davanzo, B., Emerson, R. E., Lisy, M., Koniaris, L. G., & Kays, J. K. (2018). Solitary fibrous tumor. Translational gastroenterology and hepatology, 3, 94. https://doi.org/10.21037/tgh.2018.11.02
6. Prasad, M., Corban, M. T., Henry, T. D., Dietz, A. B., Lerman, L. O., & Lerman, A. (2020). Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. Cardiovascular research, 116(8), 1424-1433. https://doi.org/10.1093/cvr/cvaa027
Alternate Names
CD34, HPCA1
Gene Symbol
CD34
Additional CD34 Products
Product Documents for Recombinant Human CD34 His Protein
Product Specific Notices for Recombinant Human CD34 His Protein
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...